Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification
Complements Stainless Steel ATF Technology with Innovative Single-Use Format Improves Ease of Use for Biopharmaceutical Manufacturing Customers Offers Equivalent High Performance to Stainless Steel XCell™ ATF With Faster Implementation WALTHAM, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its single-use version of XCell™ ATF, a proprietary cell retention system used by biologic drug manufacturers to intensify cell culture and improve the efficiency and productivity of upstream processes. This innovative new single-use format, which will be offered alongside the existing stainless steel line, significantly reduces implementation time and improves overall ease of use for Repligen’s biopharmaceutical manufacturing customers. The new XCell ATF format aligns with single-use and continuous processing workflows that biomanufacturers are increasingly